Arjan Barendrecht

Arjan Barendrecht

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2017 in Blood
Verified
Journal Article
Open access
PDF file
JVJohan J. F. Verhoef
Johan J. F. Verhoef
ABArjan Barendrecht
Arjan Barendrecht
KNKatrin F. Nickel
Katrin F. Nickel
KDKim Dijkxhoorn
Kim Dijkxhoorn
EKEllinor Kenne
Ellinor Kenne
CMCoen Maas
Coen Maas
Key Points: Activated platelets expose insoluble membrane-associated polyphosphate nanoparticles that are complexed with divalent metal ions. Platelet polyphosphate nanoparticles, but not soluble polyphosphate polymers, activate the contact system.

25 March 2014 in Circulation
Verified
Journal Article
Closed access
PDF file
CTClaudia Tersteeg
Claudia Tersteeg
SMSteven de Maat
Steven de Maat
SMSimon F. De Meyer
Simon F. De Meyer
MSMichel W.J. Smeets
Michel W.J. Smeets
ABArjan Barendrecht
Arjan Barendrecht
CMCoen Maas
Coen Maas
Background—: Von Willebrand factor (VWF) multimer size is controlled through continuous proteolysis by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type I motif, member 13). This prevents spontaneous platelet agglutination and microvascular obstructions. ADAMTS13 deficiency is associated with thrombotic thrombocytopenic purpura, in which life-threatening episodes of microangiopathy damage kidneys, heart, and brain. Enigmatically, a complete ADAMTS13 deficiency does not lead to continuous microangiopathy. We hypothesized that plasmin, the key enzyme of the fibrinolytic system, serves as a physiological backup enzyme for ADAMTS13 in the degradation of pathological platelet–VWF complexes. Methods and Results—: Using real-time microscopy, we determined that plasmin rapidly degrades platelet–VWF complexes on endothelial cells in absence of ADAMTS13, after activation by urokinase-type plasminogen activator or the thrombolytic agent streptokinase. Similarly, plasmin degrades platelet–VWF complexes in platelet agglutination studies. Plasminogen directly binds to VWF and its A1 domain in a lysine-dependent manner, as determined by enzyme-linked immunosorbent assay. Plasma levels of plasmin–α 2 -antiplasmin complexes increase with the extent of thrombocytopenia in patients with acute episodes of thrombotic thrombocytopenic purpura, independent of ADAMTS13 activity. This indicates that plasminogen activation takes place during microangiopathy. Finally, we show that the thrombolytic agent streptokinase has therapeutic value for Adamts13 −/− mice in a model of thrombotic thrombocytopenic purpura. Conclusions—: We propose that plasminogen activation on endothelial cells acts as a natural backup for ADAMTS13 to degrade obstructive platelet–VWF complexes. Our findings indicate that thrombolytic agents may have therapeutic value in the treatment of microangiopathies and may be useful to bypass inhibitory antibodies against ADAMTS13 that cause thrombotic thrombocytopenic purpura.

1 July 2020 in Blood Advances
Verified
Journal Article
Closed access
AJA. J. Gerard Jansen
A. J. Gerard Jansen
TSThom Spaan
Thom Spaan
HLHui Zhi Low
Hui Zhi Low
DIDaniele Di Iorio
Daniele Di Iorio
JBJudith van den Brand
Judith van den Brand
EVErhard van der Vries
Erhard van der Vries
Thrombocytopenia is a common complication of influenza virus infection, and its severity predicts the clinical outcome of critically ill patients. The underlying cause(s) remain incompletely understood. In this study, in patients with an influenza A/H1N1 virus infection, viral load and platelet count correlated inversely during the acute infection phase. We confirmed this finding in a ferret model of influenza virus infection. In these animals, platelet count decreased with the degree of virus pathogenicity varying from 0% in animals infected with the influenza A/H3N2 virus, to 22% in those with the pandemic influenza A/H1N1 virus, up to 62% in animals with a highly pathogenic A/H5N1 virus infection. This thrombocytopenia is associated with virus-containing platelets that circulate in the blood. Uptake of influenza virus particles by platelets requires binding to sialoglycans and results in the removal of sialic acids by the virus neuraminidase, a trigger for hepatic clearance of platelets. We propose the clearance of influenza virus by platelets as a paradigm. These insights clarify the pathophysiology of influenza virus infection and show how severe respiratory infections, including COVID-19, may propagate thrombocytopenia and/or thromboembolic complications.

28 April 2014 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
THThijs C. van Holten
Thijs C. van Holten
OBOnno B. Bleijerveld
Onno B. Bleijerveld
PWPatrick Wijten
Patrick Wijten
PGPhilip G. de Groot
Philip G. de Groot
AHAlbert Heck
Albert Heck
MRMark Roest
Mark Roest
Aims Platelets are a natural source of growth factors, cytokines and chemokines, that regulate angiogenesis and inflammation. It has been suggested that differential release of pro- and anti-angiogenic growth factors from platelet α-granules by protease-activated receptors (PAR) 1 and 4 may be important for the regulation of angiogenesis. We aimed to compare the releasates of unstimulated platelets with PAR-1- and PAR-4-stimulated platelets. Methods and results The release of β-thromboglobulin, platelet factor (PF)-4, thrombospondin, platelet-derived growth factor (PDGF)-A/B, regulated and normal T-cell expressed and secreted (RANTES/CCL5), endostatin, CXCL12, and vascular endothelial growth factor (VEGF) was measured with enzyme-linked immunosorbent assay (ELISA). Mass spectrometry (MS)-based quantitative proteomics identified 93 proteins from platelets stimulated with PAR-1 and PAR-4. A strong correlation between the factors released after either stimulus was observed (Spearman's r 0.94, P < 0.001). Analysis with ELISA showed that stimulation with PAR-1 or PAR-4 lead to non-differential release of β-thromboglobulin, PF-4, thrombospondin, PDGF-A/B, RANTES/CCL5, endostatin, CXCL12, and VEGF. Release of thrombospondin was slightly lower after PAR-1 stimulation (7.2 μg/mL), compared with PAR-4 induced release (9.8 μg/mL; P < 0.05). Conclusions Both ELISA on established α-granule proteins and MS-based quantitative proteomics showed that the most abundant α-granule proteins are released in similar quantities from platelets after stimulation with either PAR-1 or PAR-4. Our findings provide evidence against the hypothesis that PAR-1 and PAR-4 stimulation of platelets trigger differential release of alpha-granule, but further studies are needed to draw conclusions for physiological conditions.

26 February 2007 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MRM. Roest
M. Roest
THT. M. Van Himbergen
T. M. Van Himbergen
ABArjan Barendrecht
Arjan Barendrecht
PPP. H. M. Peeters
P. H. M. Peeters
YSY. T. Van Der Schouw
Y. T. Van Der Schouw
HVH. A. M. Voorbij
H. A. M. Voorbij

1 December 2017 in European Journal of Pharmacology
Verified
Journal Article
Open access
Saskia C.A. De JagerSaskia C.A. De Jager
Saskia C.A. De Jager
JMJohn A.L. Meeuwsen
John A.L. Meeuwsen
FPFreeke M. van Pijpen
Freeke M. van Pijpen
GZGerbrand A. Zoet
Gerbrand A. Zoet
ABArjan Barendrecht
Arjan Barendrecht
HRHester M. Den Ruijter
Hester M. Den Ruijter
Atherosclerosis is the major underlying pathology of cardiovascular disease (CVD). The risk for CVD is increased in women with a history of preeclampsia. Multiple studies have indicated that accelerated atherosclerosis underlies this increased CVD risk. Furthermore, it has been suggested that endothelial dysfunction and inflammation play an important role in the increased CVD risk of women with preeclampsia. Rupture or erosion of atherosclerotic plaques can induce the formation of thrombi that underlie the onset of acute clinical CVD such as myocardial infarction and stroke. In relatively young women, cardiovascular events are mainly due to plaque erosions. Eroded plaques have a distinct morphology compared to ruptured plaques, but have been understudied as a substrate for CVD. The currently available evidence points towards lesions with features of stability such as high collagen content and smooth muscle cells and with distinct mechanisms that further promote the pro-thrombotic environment such as Toll Like Receptor (TLR) signaling and endothelial apoptosis. These suggested mechanisms, that point to endothelial dysfunction and intimal thickening, may also play a role in preeclampsia. Pregnancy is considered a stress test for the cardiovascular system with preeclampsia as an additional pathological substrate for earlier manifestation of vascular disease. This review provides a summary of the possible common mechanisms involved in preeclampsia and accelerated atherosclerosis in young females and highlights plaque erosion as a likely substrate for CVD events in women with a history of preeclampsia.